174 related articles for article (PubMed ID: 16893436)
1. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
Citrome L; Stroup TS
Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436
[TBL] [Abstract][Full Text] [Related]
2. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
Nasrallah HA
J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
[TBL] [Abstract][Full Text] [Related]
3. The CATIE schizophrenia trial: results, impact, controversy.
Manschreck TC; Boshes RA
Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
[TBL] [Abstract][Full Text] [Related]
4. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
[TBL] [Abstract][Full Text] [Related]
5. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
Weiden PJ
J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
[TBL] [Abstract][Full Text] [Related]
6. Compelling or irrelevant? Using number needed to treat can help decide.
Citrome L
Acta Psychiatr Scand; 2008 Jun; 117(6):412-9. PubMed ID: 18479317
[TBL] [Abstract][Full Text] [Related]
7. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
8. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.
Novick D; Ascher-Svanum H; Zhu B; Brnabic A; Stauffer V; Peng X; Karagianis J; Perrin E
Pharmacopsychiatry; 2010 May; 43(3):81-5. PubMed ID: 20446228
[TBL] [Abstract][Full Text] [Related]
9. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
10. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP
J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332
[TBL] [Abstract][Full Text] [Related]
11. [Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study].
Gutiérrez-Suela F
Farm Hosp; 2008; 32(2):83-90. PubMed ID: 18783707
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.
Citrome L; Kantrowitz J
Expert Rev Neurother; 2008 Jul; 8(7):1079-91. PubMed ID: 18590478
[TBL] [Abstract][Full Text] [Related]
14. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of treatment effects in schizophrenia.
Stroup TS
Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
[TBL] [Abstract][Full Text] [Related]
16. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
Glazer WM; Conley RR; Citrome L
CNS Spectr; 2006 Sep; 11(9 Suppl 10):1-13; quiz 14. PubMed ID: 16946697
[TBL] [Abstract][Full Text] [Related]
17. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence.
Jakovljević M
Psychiatr Danub; 2009 Dec; 21(4):446-52. PubMed ID: 19935477
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness trials in chronic schizophrenic patients: CATIE. What can we learn?].
Leiderman EA
Vertex; 2009; 20(84):129-35. PubMed ID: 19543564
[TBL] [Abstract][Full Text] [Related]
19. Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T.
Citrome L
Psychiatry (Edgmont); 2007 Oct; 4(10):23-9. PubMed ID: 20428308
[TBL] [Abstract][Full Text] [Related]
20. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
